ADORA2A and Parkinson disease: Another adenosine A2A receptor antagonist, tozadenant was safe, well tolerated and effective in reducing off time in PD patients in phase II trial but phase III clinical trial was discontinued because of serious adverse events (agranulocytosis) [23, 133, 138].